ESCRS Today looks at 25 Years of Progress in CXL
Innovations in Corneal Cross-Linking (CXL): A Look at 25 Years of Progress
Mark Hillen
September 14, 2024
Innovations in Corneal Cross-Linking (CXL): A Look at 25 Years of Progress
Monday, September 9 is the last day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Sunday, September 8th is the third day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Saturday, September 7 is the second day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons.
Friday, September 6 was the first day of the ESCRS 2024 meeting of the European Society of Cataract and Refractive Surgeons. Here’s a collection of images from that day.
The STEP system utilizes two parameters: the minimum overall stromal thickness (ST) and the standard deviation of epithelial thickness (EP). This approach provides a more detailed understanding of keratoconus progression, offering insights that may assist in clinical decisions, especially concerning corneal cross-linking (CXL) protocols.
Here’s an overview of what ELZA’s surgeons and researchers are presenting in Barcelona this year. ELZA at ESCRS 2024.
ELZA’s research has led to the development of portable corneal cross-linking devices which democratize access to essential eye care, transforming treatment for keratoconus and infectious keratitis in low-to-middle-income countries.
Discover the latest advancements in keratoconus treatment with the ELZA Institute’s innovative techniques: transPRK, PACE, and All Femto-CAIRS, as featured in The Ophthalmologist.
In a recent publication in “Ophta,” Dr. Emilio Torres-Netto, Prof. Dr. Farhad Hafezi, and Dr. Mark Hillen present a review on the application of a well-established antihypertensive medication, losartan, for treating corneal opacities.
